Hermes Investment Management Ltd. Lowers Stake in Bio-Rad Laboratories, Inc. (BIO)

Hermes Investment Management Ltd. cut its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 194,096 shares of the medical research company’s stock after selling 6,744 shares during the period. Hermes Investment Management Ltd. owned about 0.65% of Bio-Rad Laboratories worth $43,132,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $113,000. Pacad Investment Ltd. bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $113,000. Turner Investments LLC bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $136,000. Capital Analysts LLC bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $170,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Bio-Rad Laboratories by 12.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 815 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 90 shares during the period. Institutional investors and hedge funds own 62.84% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/20/hermes-investment-management-ltd-lowers-stake-in-bio-rad-laboratories-inc-bio.html.

In other news, EVP Michael Crowley sold 700 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the transaction, the executive vice president now owns 2,060 shares in the company, valued at $444,774.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 28.29% of the stock is currently owned by company insiders.

A number of research firms have recently issued reports on BIO. Zacks Investment Research cut Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, October 12th. Deutsche Bank AG restated a “buy” rating and set a $255.00 price objective on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. TheStreet cut Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Jefferies Group LLC restated a “buy” rating and set a $275.00 price objective on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. Finally, Wells Fargo & Co began coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $260.00.

Bio-Rad Laboratories, Inc. (BIO) traded up 1.32% during mid-day trading on Friday, hitting $221.94. The stock had a trading volume of 146,531 shares. The firm has a market capitalization of $6.58 billion, a price-to-earnings ratio of 438.62 and a beta of 0.91. The stock’s 50 day moving average price is $222.91 and its 200 day moving average price is $221.60. Bio-Rad Laboratories, Inc. has a one year low of $154.89 and a one year high of $242.79.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Scie

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $113,000. Pacad Investment Ltd. bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $113,000. Turner Investments LLC bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $136,000. Capital Analysts LLC bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $170,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Bio-Rad Laboratories by 12.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 815 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 90 shares during the period. Institutional investors and hedge funds own 62.84% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/20/hermes-investment-management-ltd-lowers-stake-in-bio-rad-laboratories-inc-bio.html.

In other news, EVP Michael Crowley sold 700 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the transaction, the executive vice president now owns 2,060 shares in the company, valued at $444,774.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 28.29% of the stock is currently owned by company insiders.

A number of research firms have recently issued reports on BIO. Zacks Investment Research cut Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, October 12th. Deutsche Bank AG restated a “buy” rating and set a $255.00 price objective on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. TheStreet cut Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Jefferies Group LLC restated a “buy” rating and set a $275.00 price objective on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. Finally, Wells Fargo & Co began coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $260.00.

Bio-Rad Laboratories, Inc. (BIO) traded up 1.32% during mid-day trading on Friday, hitting $221.94. The stock had a trading volume of 146,531 shares. The firm has a market capitalization of $6.58 billion, a price-to-earnings ratio of 438.62 and a beta of 0.91. The stock’s 50 day moving average price is $222.91 and its 200 day moving average price is $221.60. Bio-Rad Laboratories, Inc. has a one year low of $154.89 and a one year high of $242.79.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply